[go: up one dir, main page]

CN111819177A - 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 - Google Patents

一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN111819177A
CN111819177A CN201980013553.1A CN201980013553A CN111819177A CN 111819177 A CN111819177 A CN 111819177A CN 201980013553 A CN201980013553 A CN 201980013553A CN 111819177 A CN111819177 A CN 111819177A
Authority
CN
China
Prior art keywords
compound
formula
crystal form
degrees
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980013553.1A
Other languages
English (en)
Other versions
CN111819177B (zh
Inventor
熊剑
陈小新
王晶晶
刘卓伟
陈新海
刘呈武
谢程
龙超峰
李鹏
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CN111819177A publication Critical patent/CN111819177A/zh
Application granted granted Critical
Publication of CN111819177B publication Critical patent/CN111819177B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种吡啶并吡唑类化合物晶型、盐型及其制备方法，还包括所述晶型在制备抗流感病毒药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (50)

  1. PCT国内申请，权利要求书已公开。
CN201980013553.1A 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 Active CN111819177B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810180641 2018-03-05
CN2018101806418 2018-03-05
PCT/CN2019/076916 WO2019170067A1 (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN111819177A true CN111819177A (zh) 2020-10-23
CN111819177B CN111819177B (zh) 2022-03-04

Family

ID=67846865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980013553.1A Active CN111819177B (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Country Status (11)

Country Link
US (1) US11535613B2 (zh)
EP (1) EP3763713A4 (zh)
JP (1) JP7031002B2 (zh)
KR (1) KR102484804B1 (zh)
CN (1) CN111819177B (zh)
AU (1) AU2019230497B2 (zh)
CA (1) CA3092315C (zh)
NZ (1) NZ767352A (zh)
RU (1) RU2769050C1 (zh)
TW (1) TWI794433B (zh)
WO (1) WO2019170067A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648247A (zh) * 2021-02-03 2023-08-25 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CN116829539A (zh) * 2021-03-11 2023-09-29 上海济煜医药科技有限公司 吡啶氮氧化合物晶型及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102312088B1 (ko) * 2016-09-05 2021-10-14 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 항인플루엔자 바이러스 피리미딘 유도체
JP7450017B2 (ja) * 2019-07-22 2024-03-14 広東衆生睿創生物科技有限公司 ピリミジン誘導体の優位な塩形およびその結晶形
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
WO2021175173A1 (zh) * 2020-03-06 2021-09-10 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102050712B1 (ko) 2009-06-17 2019-12-02 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CN103403000B (zh) * 2011-01-14 2017-05-31 斯派罗吹耐姆公司 固体形式的促旋酶抑制剂（r）‑1‑乙基‑3‑[6‑氟‑5‑[2‑（1‑羟基‑1‑甲基‑乙基）嘧啶‑5‑基]‑7‑（四氢呋喃‑2‑基）‑1氢‑苯并咪唑‑2‑基]脲
US10597390B2 (en) * 2014-08-08 2020-03-24 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
CN109477425A (zh) * 2016-03-07 2019-03-15 何宜科技能源公司 一种生成和分配用于内燃发动机的第二燃料的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648247A (zh) * 2021-02-03 2023-08-25 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CN116648247B (zh) * 2021-02-03 2025-08-05 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CN116829539A (zh) * 2021-03-11 2023-09-29 上海济煜医药科技有限公司 吡啶氮氧化合物晶型及其应用
CN116829539B (zh) * 2021-03-11 2025-11-25 上海济煜医药科技股份有限公司 吡啶氮氧化合物晶型及其应用

Also Published As

Publication number Publication date
US11535613B2 (en) 2022-12-27
TWI794433B (zh) 2023-03-01
JP2021514967A (ja) 2021-06-17
WO2019170067A1 (zh) 2019-09-12
US20200407354A1 (en) 2020-12-31
EP3763713A1 (en) 2021-01-13
CA3092315A1 (en) 2019-09-12
CA3092315C (en) 2023-08-29
RU2769050C1 (ru) 2022-03-28
EP3763713A4 (en) 2021-11-24
JP7031002B2 (ja) 2022-03-07
AU2019230497B2 (en) 2021-08-05
TW201938558A (zh) 2019-10-01
NZ767352A (en) 2023-05-26
KR102484804B1 (ko) 2023-01-04
AU2019230497A1 (en) 2020-09-17
CN111819177B (zh) 2022-03-04
KR20200124710A (ko) 2020-11-03

Similar Documents

Publication Publication Date Title
CN111819177A (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
CN113260613B (zh) 一种egfr抑制剂的盐、晶型及其制备方法
CN109071567B (zh) 抗流感小分子化合物及其制备方法和用途
EP4276099A1 (en) Pyridone multiple-membered ring derivatives and use thereof
US12252487B2 (en) Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
Yang et al. Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1
CN112771048B (zh) 流感病毒复制抑制剂及其中间体和用途
CN111233962A (zh) 一种流感病毒神经氨酸酶抑制剂及其制备方法与应用
CN108473428A (zh) 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
HK40030970A (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
US20230010367A1 (en) Related substance of linagliptin intermediate and synthesis method thereof
EP3819297A1 (en) Crystal forms of thiazole compound and application thereof
CN113480445B (zh) 一种草酰胺类神经氨酸酶抑制剂及其制备方法与应用
CN111909174B (zh) 吡啶酮衍生物的晶型及制备方法和应用
CN111196791B (zh) 一种手性γ-丁内酯衍生物及其合成方法和应用
JPS6183163A (ja) 抗腫瘍剤
CN116323593A (zh) 一种嘧啶衍生物的晶型及其制备方法
CN116655635B (zh) 黑茶茶碱衍生物及在制备药物中的应用
CN109160902B (zh) 一种用于治疗肿瘤的不对称双喹唑啉席夫碱衍生物及其制备与医药用途
CN111116551A (zh) 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物
CN102702116B (zh) 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
CN108358855B (zh) 一类含二苯甲胺的喹唑啉衍生物及其应用
HK40030970B (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
CN106243104B (zh) 一种对萘醌与嘧啶杂合体及其合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40030970

Country of ref document: HK

CB02 Change of applicant information

Address after: 510700 Room 501, building D, 288 Shenzhou Road, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Guangdong Raynovent Biotech Co.,Ltd.

Address before: 518000 No.3, 3rd floor, phase I, comprehensive Xinxing, No.1 Haihong Road, Fubao community, Fubao street, Futian District, Shenzhen City, Guangdong Province

Applicant before: Guangdong Raynovent Biotech Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant